In a recent report, the phase 3 randomized ADAURA trial, which investigated the efficacy and safety of osimertinib as adjuvant treatment compared with placebo after adjuvant chemotherapy in patients with completely resected stage IB to IIIA EGFR-mutated NSCLC, showed significant improvement in disease-free survival (DFS) in the adjuvant osimertinib arm [20]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.